Meridian Medical Technologies has issued a nationwide, voluntary recall of its Mylan EpiPen and EpiPen Jr. allergy shots.
The company said that some of devices may contain a defective part that prevents the injector from activating in the event of an allergic reaction.
“While the number of reported failures is small, EpiPen products that potentially contain a defective part are being recalled because of the potential for life-threatening risk if a severe allergic reaction goes untreated,” the company said in a statement.
The maker of the EpiPen will start selling a generic version in the wake of criticism about steep price increases.
Mylan said it expected to start selling a cheaper generic product “in several weeks” at a list price of $300 (£230).
That is about half the list price of the existing product, which is used in emergencies for severe food and insect allergies.
The cost of EpiPens in the US has risen by 500% in less than a decade.
Mylan said the generic version would be identical to the branded EpiPen, which costs $600 for two doses.